<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 12, Issue 4</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>October- December, 2020</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Anti-epileptic agents: Recent developments and structureactivity relationship studies</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>154</FirstPage>
<LastPage>158</LastPage>
<AuthorList>
<Author>
<FirstName>Bhaskar</FirstName>
<LastName>Sahu</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Ravi Ranjan</FirstName>
<LastName>Kumar</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Bhupinder</FirstName>
<LastName>Kumar</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract/>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Anti-epileptic drugs, chemistry of epilepsy, epilepsy, recent developments</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13813&title=Anti-epileptic agents: Recent developments and structureactivity relationship studies</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Angelova V, Karabeliov V, Andreeva-Gateva PA, Tchekalarova J. Recent developments of hydrazide/hydrazone derivatives and their analogs as anticonvulsant agents in animal models. Drug Dev Res 2016;77:379-92.
2. Banerjee PN, Filippi D, Hauser WA. The descriptive epidemiology of epilepsy-a review. Epilep Res 2009;85:31-45.
3. Zayed MF, Ihmaid SK, Ahmed HE, El-Adl K, Asiri AM, Omar AM. Synthesis, modelling, and anticonvulsant studies of new quinazolines showing three highly active compounds with low toxicity and high affinity to the GABA-a receptor. Molecules 2017;22:188.
4. Reddy DS. Pharmacotherapy of catamenial epilepsy. Indian J Pharmacol 2005;37:288.
5. Zhang L, Jia Y, Wang Y. The clinical characters and gene detection in a familial temporal lobe epilepsy with auditory aura. J Clin Neurosci 2020;74:268-70.
6. Zhang L, Zhu X, Zou X, Chen L. Factors predicting uncontrolled seizures in epilepsy with auditory features. Seizure 2019;65:55-61.
7. Metcalf CS, West PJ, Thomson KE, Edwards SF, Smith MD, White HS, et al. Development and pharmacologic characterization of the rat 6 Hz model of partial seizures. Epilepsia 2017;58:1073-84.
8. Willems LM, Zand;ouml;llner JP, Paule E, Schubert-Bast S, Rosenow F, Strzelczyk A. Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: Systematic review of current evidence. Exp Rev Clin Pharmacol 2018;11:309-24.
9. Pitkand;auml;nen A, Ndode-Ekane XE, Lapinlampi N, Puhakka N. Epilepsy biomarkerstoward etiology and pathology specificity. Neurobiology of disease. 2019;123:42-58.
10. Chizhov AV, Sanin AE. A simple model of epileptic seizure propagation: Potassium diffusion versus axo-dendritic spread. PLoS One 2020;15:e0230787.
11. Pintea B, Hampel K, Bostrand;ouml;m J, Surges R, Vatter H, Lendvai IS, et al. Extended long-term effects of cervical vagal nerve stimulation on headache intensity/ frequency and affective/cognitive headache perception in drug resistant complex-partial seizure patients. Neuromodulation 2017;20:375-82.
12. Maksimenko VA, van Heukelum S, Makarov VV, Kelderhuis J, Land;uuml;ttjohann A, Koronovskii AA, et al. Absence seizure control by a brain computer interface. Sci Rep 2017;7:1-8.
13. Gil-Land;oacute;pez FJ, Montoya J, Falip M, Aparicio J, Land;oacute;pez-Gonzand;aacute;lez FJ, Toledano R, et al. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures. Acta Neurol Scand 2018;138:122-9.
14. Liu F, Wang Y, Li M, Wang W, Li R, Zhang Z, et al. Dynamic functional network connectivity in idiopathic generalized epilepsy with generalized tonic-clonic seizure. Hum Brain Map 2017;38:957-73.
15. Grande-Martand;iacute;n A, Pardal-Fernand;aacute;ndez JM, Carrascosa-Romero MC, De Cabo C. Tonic seizure status epilepticus triggered by valproate in a child with Doose syndrome. Neuropediatrics 2016;47:187-9.
16. Beniczky S, Rubboli G, Covanis A, Sperling MR. Absence-to-bilateral-tonicclonic seizure: A generalized seizure type. Neurology 2020;95:e2009-15.
17. Shorvon SD. The etiologic classification of epilepsy. Epilepsia 2011;52:1052-7.
18. Wang Y, Li Z, Feng L, Bai H, Wang C. Hardware design of multiclass SVM classification for epilepsy and epileptic seizure detection. IET Circ Dev Syst 2017;12:108-15.
19. Engelborghs S, D’hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg 2000;100:201-13.
20. Patel DC, Tewari BP, Chaunsali L, Sontheimer H. Neuron-glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci 2019;20:282-97.
21. Kothayer H, Ibrahim SM, Soltan MK, Rezq S, Mahmoud SS. Synthesis, in vivo and in silico evaluation of novel 2, 3-dihydroquinazolin-4 (1H)-one derivatives as potential anticonvulsant agents. Drug Dev Res 2019;80:343-52.
22. Acar MF, Sari S, Dalkara S. Synthesis, in vivo anticonvulsant testing, and molecular modeling studies of new nafimidone derivatives. Drug Dev Res 2019;80:606-16.
23. Wei F, Yan LM, Su T, He N, Lin ZJ, Wang J, et al. Ion channel genes and epilepsy: Functional alteration, pathogenic potential, and mechanism of epilepsy. Neurosci Bull 2017;33:455-77.
24. Kocharov SL, Panosyan H, Chmielewski J, Gworek B, ?uszczki JJ. Synthesis and anticonvulsant properties of some n-aryl and n-arylaminomethyl derivatives of 3-p-isopropoxyphenylpyrrolidine-2,5-dione. Acta Pol Pharm Drug Res 2019;76:265-73.
25. Ding J, Cao FD, Geng YR, Tian Y, Li P, Li XF, et al. Synthesis and in vitro antiepileptic activities of novel [1, 2, 4]-triazolo [1, 5-a] pyrimidin-7 (4H)-one derivatives. J Asian Natl Prod Res 2019;21:1190-204.
26. Rafiei LS, Asadi M, Hosseini FS, Amanlou A, Biglar M, Amanlou M. Synthesis and evaluation of anti-epileptic properties of new phthalimide-4, 5-dihydrothiazole-amide derivatives. Pol Aromat Comp 2020. Doi: 10.1080/10406638.2020.1776345
27. Song JH, Bae SM, Bae WR, Huh JS, Chen Y, Jeong IS, et al. Synthesis and antiepileptic activity evaluation of valproic acid derivatives by niche chemistry. Bull Korean Chem Soc 2020;41:558-62.
28. Rawat P, Verma SM. Design and synthesis of chroman derivatives with dual antibreast cancer and antiepileptic activities. Drug Design Dev Ther 2016;10:2779.
29. Gunia-Krzy?ak A, ?elaszczyk D, Rapacz A, ?es?awska E, Waszkielewicz AM, Pa?czyk K, et al. Structure-anticonvulsant activity studies in the group of (E)- N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3. Bioorg Med Chem 2017;25:471-82.
30. Tanaka T, Yajima N, Kiyoshi T, Miura Y, Iwama S. N-alkyl-[1, 1’-biphenyl]-2- sulfonamide derivatives as novel broad spectrum anti-epileptic drugs with efficacy equivalent to that of sodium valproate. Bioorg Med Chem Lett 2017;27:4118-21.
31. Yang S, Lu D, Ouyang P. Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy. Bioorg Med Chem Lett 2018;28:3004-8.
32. Dwivedi J, Devi K, Asmat Y, Jain S, Sharma S. Synthesis, characterization, antibacterial and antiepileptic studies of some novel thiazolidinone derivatives. J Saudi Chem Soc 2016;20:S16-20.
33. Auer T, Schreppel P, Erker T, Schwarzer C. Functional characterization of novel bumetanide derivatives for epilepsy treatment. Neuropharmacology 2020;162:107754.</References>
</References>
</Journal>
</Article>
</ArticleSet>